Bladder Cancer

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

"The Bladder CARE Assay's quantitative nature sets it apart from other tests," said Siamak Daneshmand, MD.

Experts discuss grading, staging, and risk stratification of Non-Muscle Invasive Bladder Cancer (NMIBC). Panelists highlight differentiation between the risks of recurrence and progression, emphasizing the importance of categorizing patients into low, intermediate, and high-risk groups based on various factors, including tumor size, grade, and history of recurrence. The importance of continuous prospective observation of patients with NMIBC is emphasized.

Experts in urology discuss the importance of evaluation to accurately identify the stage and grade of NMIBC, which plays a crucial role in determining the risk category focusing on the distinction between low and high-grade tumors and the significance for each patient with NMIBC​​.

“When it comes to this, I think having a great team around you is really so important,” says Bree Duncan, RN, BSN.

The approval is supported by findings from the phase 3 EV-302 trial, which showed that the combination led to significant improvements in overall survival and progression-free survival compared with chemotherapy.

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.

Expert perspectives on treatment options available for patients with bladder cancer and the role of trimodal therapy.

A panel of experts on bladder cancer provide an overview of the stratification, natural history, and treatment of bladder cancer.

An expert urologist reviews the clinical hallmarks of high-risk BCG-unresponsive NMIBC and discusses the unmet needs and treatment goals.

Neal Shore, MD, FACS, provides an overview of BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), with a focus on patient presentation and risk stratification.

“The impressive duration of response, still expanding with 6/8 responses ongoing, is indicative of restoration of a lasting immunologic tumor control in advanced solid tumor patients,” says Eugen Leo, MD, PhD, MBA

The designations, which will expedite the development and regulatory review of cretostimogene grenadenorepvec in this setting, are supported by results from the phase 3 BOND-003 trial.

The application is based on results from the phase 3 CheckMate-901 trial.

The designation, which will expedite the development and regulatory review of TAR-200 in this setting, is based on findings from the phase 2b SUNRISE-1 trial.

“[Although] not yet ready for prime time, ctDNA is being investigated as a very promising non-invasive plasma biomarker of invasive or advanced-stage upper tract urothelial carcinoma,” says Heather L. Huelster, MD.

The priority review is based on results from the phase 3 EV-302 trial.

Scott T. Tagawa, MD, MS, FACP, FASCO, offers a comprehensive look at the evolving treatment landscape, with a focus on practical considerations and ongoing research.

An overview of the toxicity profile of enfortumab vedotin and pembrolizumab in patients being treated for urothelial carcinoma.

Dr. Tagawa offers his initial impressions on the second patient case and discusses data on enfortumab vedotin plus pembrolizumab for patients with urothelial carcinoma.

An expert on urothelial carcinoma reviews the case of a 76-year-old patient with advanced, resectable urothelial carcinoma.

Scott T. Tagawa, MD, MS, FACP, FASCO, a urothelial carcinoma specialist, discusses adverse events seen in patients receiving sacituzumab govitecan.

A medical oncologist specializing in urothelial carcinoma reviews key data on erdafitinib, enfortumab vedotin, and sacituzumab govitecan.

An expert on urothelial carcinoma gives an overview of disease risk factors, patient diagnosis, and testing practices.